Trial Profile
Biological study of the effect of GW572016 (Lapatinib) in cell apoptosis in ductal carcinoma in situ in patients with HER2-positive breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2012
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Ductal carcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Biomarker; Pharmacodynamics
- 04 May 2012 Status changed from recruiting to completed, according to the European Clinical Trials Database.
- 23 Aug 2011 New trial record